Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald P Taylor

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
Methods (San Diego, Calif.)|July 27, 2013
The role of complement in mAb-based therapies of cancerRonald P Taylor, Margaret A Lindorfer
Molecular Pharmacology|June 20, 2014
Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesRonald P Taylor, Margaret A Lindorfer
Clinical Immunology (Orlando, Fla.)|December 18, 2002
Visualization of the transfer reaction: tracking immune complexes from erythrocyte complement receptor 1 to macrophagesMaria L Craig, Alexander J Bankovich, Ronald P Taylor
The New England Journal of Medicine|August 31, 2012
Anti-CD20 antibody therapy for B-cell lymphomasRonald P Taylor, Margaret A Lindorfer, Clive S Zent
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2005
Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1Maria L Craig, John N Waitumbi, Ronald P Taylor
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shavingPaul V Beum, Margaret A Lindorfer, Ronald P Taylor
Alzheimer'S & Dementia (New York, N. Y.)|September 5, 2020
Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytesRonald P Taylor, Margaret A Lindorfer, John P Atkinson
Journal of Immunological Methods|July 15, 2004
Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomasPaul V Beum, Adam D Kennedy, Ronald P Taylor
Endocrine, Metabolic & Immune Disorders Drug Targets|April 9, 2008
Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?Giovanni D'Arena, Ronald P Taylor, Nicola Cascavilla, et al.
Oncoimmunology|November 20, 2012
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?Margaret A Lindorfer, Adrian Wiestner, Clive S Zent, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Methods (San Diego, Calif.)|July 27, 2013
The role of complement in mAb-based therapies of cancerRonald P Taylor, Margaret A Lindorfer
Molecular Pharmacology|June 20, 2014
Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesRonald P Taylor, Margaret A Lindorfer
Clinical Immunology (Orlando, Fla.)|December 18, 2002
Visualization of the transfer reaction: tracking immune complexes from erythrocyte complement receptor 1 to macrophagesMaria L Craig, Alexander J Bankovich, Ronald P Taylor
The New England Journal of Medicine|August 31, 2012
Anti-CD20 antibody therapy for B-cell lymphomasRonald P Taylor, Margaret A Lindorfer, Clive S Zent
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2005
Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1Maria L Craig, John N Waitumbi, Ronald P Taylor
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shavingPaul V Beum, Margaret A Lindorfer, Ronald P Taylor
Alzheimer'S & Dementia (New York, N. Y.)|September 5, 2020
Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytesRonald P Taylor, Margaret A Lindorfer, John P Atkinson
Journal of Immunological Methods|July 15, 2004
Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomasPaul V Beum, Adam D Kennedy, Ronald P Taylor
Endocrine, Metabolic & Immune Disorders Drug Targets|April 9, 2008
Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?Giovanni D'Arena, Ronald P Taylor, Nicola Cascavilla, et al.
Oncoimmunology|November 20, 2012
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?Margaret A Lindorfer, Adrian Wiestner, Clive S Zent, et al.
Pageof 10